# A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

> **NCT03912064** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 25 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Myeloproliferative Neoplasms
- Chronic Myelomonocytic Leukemia
- Myelofibrosis

## Interventions

- **DRUG:** Ipilimumab
- **BIOLOGICAL:** CD25hi Treg depleted DLI

## Key facts

- **NCT ID:** NCT03912064
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-10
- **Primary completion:** 2024-05-24
- **Final completion:** 2026-12-31
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2026-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03912064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03912064, "A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03912064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*